CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/06/22
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/22
CytomX Therapeutics to Present at Upcoming Virtual August Investor ConferencesGlobeNewsWire • 08/03/22
CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/28/22
CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022GlobeNewsWire • 07/28/22
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast CancerGlobeNewsWire • 07/06/22
CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare ConferenceGlobeNewsWire • 06/01/22
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid TumorsGlobeNewsWire • 05/26/22
CytomX Therapeutics' (CTMX) CEO Sean McCarthy on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/07/22
CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/05/22
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/05/22
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022GlobeNewsWire • 04/28/22
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of DirectorsGlobeNewsWire • 03/23/22
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022GlobeNewsWire • 03/17/22
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/02/22
CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business UpdateGlobeNewsWire • 03/01/22
CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022GlobeNewsWire • 02/22/22
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid TumorsGlobeNewsWire • 01/19/22